Paediatric Drug Optimization For Neglected Tropical Diseases
Paediatric Drug Optimization For Neglected Tropical Diseases Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Paediatric Drug Optimization For Neglected Tropical Diseases book. This book definitely worth reading, it is an incredibly well-written.
Author : World Health Organization Publisher : World Health Organization Page : 56 pages File Size : 44,8 Mb Release : 2023-11-21 Category : Business & Economics ISBN : 9789240085176
Paediatric drug optimization for neglected tropical diseases by World Health Organization Pdf
Priority-setting is the first step to enable a targeted approach to research and development. Developing a prioritized drug portfolio of the most needed formulations for children is essential to streamline researchers’ and supplier’s efforts and resources around specific dosage forms and formulations that address most urgent needs for children. In general, due to limited financial incentives, few new drugs are being developed for Neglected Tropical Diseases (NTDs). Several NTDs disproportionately affect children compared to adults and, as is the case like for most diseases affecting adults and children, the burden to children is compounded by lack of inclusion of paediatric populations in clinical trials and/or lack of age-appropriate dosing regimens and formulations. The PADO-NTD exercise concluded with a final meeting organized in September 2023 with representatives from the four prioritized disease areas to reach consensus on a final PADO-NTD priority list, watch list and research questions and discuss transversal issues for the way forward. The meeting report will include summaries of the background, discussions and deliberations of all PADO exercises, and final conclusions and outputs of the overall PADO for NTD exercises.
Author : World Health Organization Publisher : World Health Organization Page : 56 pages File Size : 50,6 Mb Release : 2024-05-30 Category : Medical ISBN : 9789240094826
Paediatric drug optimization for tuberculosis by World Health Organization Pdf
Paediatric drug optimization (PADO) exercises have been convened by the World Health Organization (WHO) for various diseases, demonstrating their potential and impact to accelerate access to optimal formulations in the context of fragmented small markets for medicines for children. The WHO Global Tuberculosis Programme has convened PADO-TB meetings since February 2019 (PADO-TB1), followed by an interim review of the PADO-TB1 priorities in September 2020. Optimization of paediatric TB medicines forms part of the key actions in the Roadmap towards ending TB in children and adolescents, third edition and contributes to the achievement of the targets for ending TB in children and adolescents set out at the second United Nations High-level Meeting on the Fight Against TB in 2023. Considering the latest WHO recommendations on drug-susceptible TB, drug-resistant TB and TB preventive treatment, recent developments in new TB medicines and formulations made available, results of clinical trials and studies, and advancements of key medicines in the TB R&D pipeline, WHO convened the second PADO-TB meeting (PADO-TB2) on 3–5 October 2023. This meeting report summarizes the proceedings, discussions and the main consensus-based outputs of the PADO-TB2 meeting: - PADO-TB2 priority list (priority formulations to be investigated/developed in the short term and essential formulations to be developed in the longer term) - PADO-TB2 watch list (promising candidates for investigation/development for children within 5–10 years) - Priority research questions.
Author : World Health Organization Publisher : World Health Organization Page : 86 pages File Size : 46,9 Mb Release : 2024-05-04 Category : Medical ISBN : 9789240091535
Global report on neglected tropical diseases 2024 by World Health Organization Pdf
This document is the second in a series of global reports describing progress towards the 2030 targets set in Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030. It describes a wide range of activities, accomplishments and challenges across the portfolio of NTDs and across all six WHO regions. The report presents epidemiological and programmatic data for 2022, which were gathered, compiled and analysed in 2023. In some cases, 2023 data are available and presented; in other cases, less recent information is included, when 2022 data are not available. In addition, it presents the main facts or events that occurred in 2023. In line with the road map’s companion document Ending the neglect to attain the Sustainable Development Goals: a framework for monitoring and evaluating progress of the road map for neglected tropical diseases 2021−2030, the report includes quantitative information on the status of the overarching, cross-cutting and disease-specific indicators. This is followed by qualitative information on each of the three road map pillars and on regional and country progress. The conclusions of the report and way forward are further complemented by annexes on cross-cutting indicator 6, status of donated medicines for treatment of NTDs, articles on NTDs published in the Weekly Epidemiological Record, target product profiles published as of 31 December 2023 and the list of global NTD reports published by WHO so far.
Author : World Health Organization Publisher : World Health Organization Page : 48 pages File Size : 51,8 Mb Release : 2022-03-25 Category : Medical ISBN : 9789240044647
Shaping the global innovation and access landscape for better paediatric medicines by World Health Organization Pdf
GAP-f’s three-year strategic plan (2022-2024) builds from the work undertaken to date by the network of leading partners, both individually and collectively, through GAP-f. With this strategy, GAP-f is excited to increase its footprint into a broader set of diseases to bring it closer to its vision of all children having equitable access to the medicines they need.
Author : World Health Organization Publisher : World Health Organization Page : 17 pages File Size : 43,7 Mb Release : 2022-11-30 Category : Medical ISBN : 9789240062047
First meeting of the WHO Strategic and Technical Advisory Group working group on access to safe, efficacious and quality-assured health products for neglected tropical diseases by World Health Organization Pdf
Author : World Health Organization Publisher : World Health Organization Page : 16 pages File Size : 45,9 Mb Release : 2023-11-30 Category : Medical ISBN : 9789240083035
Second meeting of the WHO Strategic and Technical Advisory Group working group on access to safe, efficacious and quality-assured health products for neglected tropical diseases by World Health Organization Pdf
The STAG Working Group on access to safe, efficacious and quality-assured health products for neglected tropical diseases was established in 2021 to facilitate alignment of stakeholders on strategies and best practices for improving access to medicines and other health products for NTDs. The Working Group held its second technical meeting virtually on 19 September 2023. The main outcomes of the meeting were to expand the scope of drug efficacy monitoring to include other neglected tropical diseases and to seek synergy in addressing common issues and challenges across diseases for procurement and supply chain management. In addition to the Working Group’s members, observers, invited guests and the WHO secretariat attended the meeting. This publication contains the report of the meeting and its recommendations to STAG, which will be helpful as a reference and of use to the wider NTD community.
Author : World Health Organization Publisher : World Health Organization Page : 31 pages File Size : 55,9 Mb Release : 2024-04-19 Category : Business & Economics ISBN : 9789240091276
Report of the Paediatric Regulatory Network meeting, 12-13 May 2022 by World Health Organization Pdf
The Paediatric Regulatory Network was initially created as a global paediatric working group in February 2010 in response to a recommendation from the 2008 International Conference on Drug Regulatory Authorities and as part of the World Health Organization (WHO) Better Medicines for Children Project in collaboration with the Bill & Melinda Gates Foundation, to offer a platform for discussion on paediatric regulatory considerations for national regulatory authorities. The Network was reactivated in December 2019 as a global paediatric network supporting the availability of quality-assured medical products for children, by facilitating communication, collaboration, training and regulatory harmonization across the development, registration and pharmacovigilance of paediatric medical products. The Network’s activities contribute efficiently to the implementation of World Health Assembly resolutions WHA60.20 (2007) on better medicines for children, WHA69.20 (2016) on promoting innovation and access to quality, safe, efficacious and affordable medicines for children, WHA67.20 (2014) on regulatory system strengthening for medical products and WHA67.22 (2014) on access to essential medicines.
Author : World Health Organization Publisher : World Health Organization Page : 111 pages File Size : 51,8 Mb Release : 2024-05-03 Category : Medical ISBN : 9789240091238
Report of the fifth WHO stakeholders meeting on gambiense and rhodesiense human African trypanosomiasis elimination, Geneva, Switzerland, 7-9 June 2023 by World Health Organization Pdf
Concerted efforts by national programmes, supported by public–private partnerships, nongovernmental organizations, donors and academia under the auspices and coordination of the World Health Organization (WHO), have produced important achievements in the control of human African trypanosomiasis (HAT). As a consequence, the disease was targeted for elimination as a public health problem by 2020. The Sixty-sixth World Health Assembly endorsed this goal in resolution WHA66.12 on Neglected tropical diseases, adopted in 2013. National sleeping sickness control programmes (NSSCPs) are core to progressing in the control of the disease and in adapting to the different epidemiological situations. The involvement of different partners, as well as the support and trust of long-term donors, has been crucial for these achievements. More than 20 years of partnership among WHO, Sanofi and Bayer have enabled WHO to strengthen and sustain financial, technical and material support for the implementation of control activities in countries where HAT is endemic. The long-term support from the Government of Belgium, the Bill & Melinda Gates Foundation (BMGF) and other research institutions in the Democratic Republic of the Congo (DRC) has also been essential. WHO convened the fifth stakeholders meeting on the elimination of HAT due to infection with Trypanosoma brucei gambiense (g-HAT) and Trypanosoma brucei rhodesiense (r-HAT) in Geneva, Switzerland, on 7–9 June 2023. The meeting was held again in person after the coronavirus disease (COVID-19) pandemic and jointly for both forms of the disease. The previous meetings on g-HAT held in 2014, 2016 and 2018, as well as on r-HAT in 2015, 2017 and 2019, and jointly for g-HAT and r-HAT in 2021 (8) reinforced the partnership and commitment for HAT elimination and structured the mechanisms of collaboration within the WHO network for HAT elimination. The network includes NSSCPs, groups developing new tools, international and nongovernmental organizations involved in disease control, and donors. Fewer than 1000 cases of HAT annually have been reported over the past 5 years, which is a historic achievement. The area at risk has been substantially reduced. The elimination of HAT as a public health problem at the global level has been achieved. The new road map for neglected tropical diseases (NTDs) 2021−2030 (“the road map”) with the target to interrupt the transmission of g-HAT requires the strengthened and sustained efforts of all stakeholders, national authorities and partners, under WHO coordination. It will take disproportionally high efforts and innovative strategies to find the last cases of g-HAT and neutralize its transmission. Given the limited resources and other competing public health priorities, this is a challenge that requires our joint commitment.
Author : World Health Organization Publisher : World Health Organization Page : 25 pages File Size : 47,9 Mb Release : 2024-02-19 Category : Medical ISBN : 9789240086029
Tenth meeting of the Working Group on Monitoring of Neglected Tropical Diseases Drug Efficacy, Ghent, 21 June 2023 by World Health Organization Pdf
Helminth control programmes based on preventive chemotherapy against soil?transmitted helminthiases and schistosomiasis are continuing to scale up. In 2021, the global coverage of preventive chemotherapy reached 62.2% for soil-transmitted helminthiases and 40.3% for schistosomiasis; more than 650 million individuals were treated with albendazole and mebendazole for soil-transmitted helminthiases and with praziquantel for schistosomiasis. The expansion of preventive chemotherapy can potentially risk triggering anthelminthic drug resistance and put at stake the long-term public health benefits of the intervention. Antimicrobial resistance is not yet a public health problem in human helminthiases, as opposed to helminths of veterinary importance. The Working Group on Monitoring of Neglected Tropical Diseases Drug Efficacy (“the Working Group”) was established by the World Health Organization (WHO) in 2011 with the purpose of promoting: - the establishment of a standard system for monitoring drug efficacy; - the judicious use of anthelminthics in order to sustain their efficacy and delay antimicrobial resistance; and - the testing of alternative drugs and drug combinations, should antimicrobial resistance emerge for the front-line drugs presently used in preventive chemotherapy programmes. The tenth meeting of the Working Group was held at Ghent University (Ghent, Belgium) on 21 June 2023. The meeting was chaired by Professor Jozef Vercruysse (Ghent University). The rapporteurs were Dr Bruno Levecke (Ghent University) and Dr Denise Mupfasoni (WHO Global Neglected Tropical Diseases Programme). The objectives of the meeting were: - to review the data on monitoring the efficacy of anthelminthics currently used in large-scale deworming programmes for soil-transmitted helminthiases and schistosomiasis; - to review the need for, and recommend the revision of, the WHO guidance on monitoring drug efficacy in large-scale deworming programmes; and - to review ongoing research on anthelminthic drugs (combinations).
United States. Congress. Senate. Committee on Appropriations. Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies
Author : United States. Congress. Senate. Committee on Appropriations. Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Publisher : Unknown Page : 64 pages File Size : 49,8 Mb Release : 2011 Category : Medical ISBN : UCSD:31822037823424
Food and Drug Administration's Review Process for Products to Treat Rare Diseases and Neglected Tropical Diseases by United States. Congress. Senate. Committee on Appropriations. Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Pdf
Medicinal Chemistry of Neglected and Tropical Diseases by Venkatesan Jayaprakash,Daniele Castagnolo,Yusuf Özkay Pdf
Medicinal Chemistry of Neglected and Tropical Diseases: Advances in the Design and Synthesis of Antimicrobial Agents consolidates and describes modern drug discovery and development approaches currently employed to identify effective chemotherapeutic agents for the treatment of Neglected Tropical Diseases (NTDs) from a medicinal chemistry perspective. Chapters are designed to cater to the needs of medicinal chemists who work with chemotherapeutic developments for NTDs, as well as serve as a guide to budding medicinal chemists who wish to work in this area. It will introduce rational drug design approaches adopted in designing chemotherapeutics and validated targets available for the purpose.
Author : Luis Rivas,Carmen Gil Publisher : Royal Society of Chemistry Page : 422 pages File Size : 51,6 Mb Release : 2017-10-26 Category : Science ISBN : 9781788012584
Drug Discovery for Leishmaniasis by Luis Rivas,Carmen Gil Pdf
For human health, leishmaniasis is among the most important protozoan diseases, superseded only by malaria. Globally, 10 to 12 million people are infected with 1.5 million new cases every year. The development of cheaper new drugs is urgently needed for this neglected disease that is developing resistance to current treatments. Chemotherapy remains the only treatment option for the bulk of patients. However, this is largely unaffordable for most. In the past three years numerous advances in drug discovery have been made for treating this disease by exploiting diverging metabolic pathways between the Leishmania enzymes and their hosts, using nanotechnology to target the immune cell phagolysosomes where Leishmania resides. Drug Discovery for Leishmaniasis aims to provide a perspective of the current treatments and their challenges, blended with the emerging strategies and methodologies that will drive new target appraisals and drug developments, as well as addressing the molecular basis of resistance in Leishmania. Recent studies have shown that leishmaniasis affects some of the poorest people in the world, with 95% of fatal cases occurring in only 6 countries. With the WHO goal of eliminating this public health problem in the South-east Asia Region by 2020, this book will be important for anyone who is interested in neglected tropical diseases.
Author : World Health Organization Publisher : World Health Organization Page : 32 pages File Size : 54,5 Mb Release : 2019-09-02 Category : Medical ISBN : 9789241515344
Bench aids for the diagnosis of intestinal parasites by World Health Organization Pdf
This second edition of Bench aids for the diagnosis of intestinal parasites is intended both as a practical tool for the diagnosis of intestinal parasitic infections for laboratory and field workers and as a teaching aid for students and trainees. The plates are arranged on two sides: the recto with microphotographs for the identification of eggs larvae trophozoites cysts and oocysts occurring in faeces and the verso dedicated to the different copromicroscopical methods (procedures) and main staining techniques used in parasitology. Special attention has been devoted to all graphical and pictorial contents. The decision to include the outline of an Ascaris lumbricoides egg in its relative size next to each parasitic structure fulfils the intention of visualizing the actual dimensions that the eye needs to be looking for when examining the specimens with a microscope. For each image the size of the parasite and a short description are provided to assist in the microscopical identification. Two summary plates one for helminths and the other for protozoa are also included to provide a visual overview of the different presentations of parasitic elements. The bench aids have been produced in a weatherproof plastic-sealed format that is robust and easy to use at the bench. They are recommended for use by all health workers engaged in the routine diagnosis of intestinal parasitic infections.
Nanopharmaceutical Advanced Delivery Systems by Vivek Dave,Nikita Gupta,Srija Sur Pdf
The book provides a single volume covering detailed descriptions about various delivery systems, their principles and how these are put in use for the treatment of multiple diseases. It is divided into four sections where the first section deals with the introduction and importance of novel drug delivery system. The second section deals with the most advanced drug delivery systems like microbubbles, dendrimers, lipid-based nanoparticles, nanofibers, microemulsions etc., describing the major principles and techniques of the preparations of the drug delivery systems. The third section elaborates on the treatments of diverse diseases like cancer, topical diseases, tuberculosis etc. The fourth and final section provides a brief informative description about the regulatory aspects of novel drug delivery system that is followed in various countries.